CSPC Pharmaceutical Group Ltd. announced that their drug CPO301 has been granted its third Fast Track designation by the U.S. Food and Drug Administration (FDA). This designation is for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer (Nsq-NSCLC) without EGFR mutations, who have experienced disease progression following platinum-based chemotherapy and anti-PD-$(L)$1 antibody treatment. This marks the third Fast Track designation for CPO301, following previous designations for other NSCLC treatment contexts. The Fast Track status will aid in expediting the development and registration processes for CPO301 in the U.S. and globally. No other organizations were mentioned in obtaining this grant.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.